A new treatment approach of toripalimab in combination with concurrent platinum-based chemoradiotherapy for locally advanced cervical cancer: A phase II clinical trial.

By setting a PD‐L1 CPS threshold of ≥10, we found a trend toward longer PFS in the CPS ≥10 population compared to the CPS <10 population, although the difference did not reach statistical significance (2‐year PFS: 92.8% vs. 81.2%, p = .409).

also in 111,027 other papers